Upstream Bio, Inc. (UPB) Stock Forecast & Price Target
Upstream Bio, Inc. · NASDAQ
$6.40-0.01 (-0.16%)
15-min delayed · Jul 27, 3:45 PM ET · Get real-time quotes →
The Quantellect read.Of the 6 firms covering Upstream Bio, Inc, 4 rate it Buy or better, 2 sit at Hold, and 0 rate it Sell or worse, a moderate buy consensus. The target range is very wide, $8.00 to $50.00 (about 6.3x), which points to deep disagreement over how to value the company rather than near-term timing. The average target of $33.17 sits 418% above the current $6.40. The rating mix has stayed broadly stable, with Buy-side ratings edging up from 3 to 4 over recent months. On the fundamentals, the Street sees consensus EPS building from about $-0.70 next quarter toward $-2.89 the year after.Descriptive synthesis of third-party analyst data, not a Quantellect rating or recommendation.
ANALYST CONSENSUS6 ratings
Moderate Buy
Strong Buy00%
Buy467%
Hold233%
Sell00%
Strong Sell00%
Based on 6 analysts giving stock ratings to Upstream Bio, Inc.
As of Jul, 4 of 6 firms rate UPB a Buy (2 Hold, 0 Sell), the standing distribution of every covering firm's most recent active call.
UPB EPS & revenue forecast
EPS · NEXT QUARTER
$-0.70
Range $-0.88 – $-0.46 · 9 analysts · +11% YoY
Next period, 9 analysts expect Upstream Bio, Inc. to earn $-0.70 a share (range $-0.88 – $-0.46), versus $-0.63 a year earlier. Full-year consensus is $-2.84, growing to $-2.89 the year after.
REVENUE · NEXT QUARTER
$378.9K
Range $0 – $875.0K · 9 analysts · -45% YoY
Revenue is expected to reach $378.9K (range $0 – $875.0K), -44.5% year-over-year. Full-year consensus is $2.0M, rising to $1.7M next year.
Top analysts covering Upstream Bio, Inc.
Ranked by each analyst's overall Quantellect track record across all the stocks they cover, shown with their current call on UPB.
#1
MC
Matthew Caufield
HC Wainwright & Co. · Rank #51
Buy
$36.00+462.5% to target
Overall win rate
56%
+ Follow
#2
Yasmeen Rahimi
Piper Sandler · Rank #152
Buy
$75.00+1071.9% to target
Overall win rate
34%
+ Follow
#3
TR
Tessa Romero
JP Morgan
Hold
$8.00+25.0% to target
Coverage
—
+ Follow
#4
Joseph Catanzaro
Mizuho
Buy
$50.00+681.3% to target
Coverage
—
+ Follow
#5
Cory Kasimov
Evercore ISI Group
Hold
$15.00+134.4% to target
Coverage
—
+ Follow
UPB stock forecast FAQ
What is UPB's average 12-month price target?+
The 5 analysts with a live target average $33.17 for Upstream Bio, Inc. over the next 12 months, ranging from a $50.00 high to a $8.00 low.
Is UPB stock a Buy, Sell or Hold right now?+
The current consensus is Moderate Buy. Of the 6 analyst ratings, 4 are Buy or Strong Buy, 2 are Hold, and 0 are Sell or Strong Sell.
What are the highest and lowest price targets for UPB?+
The Street-high target is $50.00 (Mizuho), and the Street-low is $8.00 (JP Morgan). The average of all 5 active targets is $33.17.
How many Wall Street analysts cover UPB?+
6 analysts have an active rating on Upstream Bio, Inc., and 5 firms carry a live 12-month price target.
Who is the most accurate analyst covering UPB?+
Among analysts who currently cover UPB, Matthew Caufield of HC Wainwright & Co. has the strongest overall Quantellect track record (Rank #51). Their current call is Buy with a $36.00 target.
What is Upstream Bio, Inc.'s projected EPS for next quarter?+
The consensus estimate is $-0.70 per share (range $-0.88 – $-0.46) across 9 analysts. Full-year EPS is projected at $-2.84, rising to $-2.89 the following year.
How much revenue is Upstream Bio, Inc. expected to report next quarter?+
Consensus revenue is $378.9K (range $0 – $875.0K). Full-year revenue is projected at $2.0M, growing to $1.7M next year.
Have analysts been upgrading or downgrading UPB lately?+
As of Jul, 4 of 6 firms rate UPB a Buy (2 Hold, 0 Sell), the standing distribution of every covering firm's most recent active call.
How are the analysts on this page ranked?+
By each analyst's overall Quantellect track record — a sample-adjusted measure of how accurate their calls have been across every stock they cover. We do not rank on their UPB calls alone, since a single stock is too small a sample to be reliable.
Which data on this page is live, and how often does it update?+
Price and daily change are 15-minute delayed market data. Analyst ratings, targets, consensus and earnings estimates are aggregated from multiple data providers and refresh daily.
Disclaimer: Ratings, price targets, consensus and earnings estimates on this page describe third-party analyst research aggregated from multiple data providers and refreshed daily; price and daily change are 15-minute delayed. These are historical opinions, not recommendations, and nothing on this page, including The Quantellect read, is a rating, a price target, or investment advice from Quantellect. Always do your own research and consult a licensed financial advisor before making investment decisions.
